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Abstract Non-invasive pulse spectrophotometry to measure indocyanine green (ICG) elimination correlates well with the
conventional invasive ICG clearance test. Nevertheless, the precision of this method remains unclear for any application,
including small-for-size liver remnants. We therefore measured ICG plasma disappearance rate (PDR) during the anhepatic
phase of orthotopic liver transplantation using pulse spectrophotometry. Measurements were done in 24 patients. The
median PDR after exclusion of two outliers and two patients with inconstant signal was 1.55%/min (95% confidence
interval [CI]=0.8–2.2). No correlation with patient age, gender, body mass, blood loss, administration of fresh frozen
plasma, norepinephrine dose, postoperative albumin (serum), or difference in pre and post transplant body weight was
detected. In conclusion, we found an ICG-PDR different from zero in the anhepatic phase, an overestimation that may arise
in particular from a redistribution into the interstitial space. If ICG pulse spectrophotometry is used to measure functional
hepatic reserve, the verified average difference from zero (1.55%/min) determined in our study needs to be taken into
account.
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Introduction
In addition to the expected volume of the liver remnant,1
quantitative (or “dynamic”) liver function tests have been
used to predict the risk of hepatic failure after liver
resection.2,3 Indocyanine green (ICG) is a nontoxic dye
extracted exclusively by hepatic parenchymal cells without
enterohepatic circulation and excreted entirely into the
bile.2,4 The ICG elimination test was originally invented to
determine hepatic blood flow, but it is in fact an integrative
measure of both hepatic perfusion and excretory function.5–7
Therefore, ICG elimination testing has been used for the past
20 years in the context of hepatic resection8 and to assess
liver functional reserve in hepatic injury and septic states; in
addition, it was found to be as accurate as more complex
scores (e.g., APACHE II and SAPS II) with respect to
outcome prediction.9–11 Moreover, ICG elimination tests are
intended to determine the suitability of a potential donor liver
and to recognize early graft dysfunction resulting from, for
example, primary delayed or nonfunction of the graft,
technical complications, and acute or chronic graft rejection
in the transplant setting.12–14
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Noninvasive pulse spectrophotometry15 allows the moni-
toring of appearance and disappearance of ICG by a
photometric device performing transcutaneous measurements
in real time. It is supposed to correlate well with the
conventional invasive ICG clearance test.16–18 In the
postoperative course, a plasma disappearance rate (PDR)
>5.0%/min seems to indicate hepatic recovery after extended
liver resections.19 In particular, in small-for-size liver
remnants (<0.8% of body weight)1,20 and in fulminant
hepatic failure, real-time prognostic tests are urgently needed
as a decision aid for indication of artificial liver support
systems like the molecular adsorbent recirculating system
(MARS).21,22 To date, clear indications for the postoperative
initiation of MARS treatment and criteria for the discontin-
uation of therapy have not been established.19
Unfortunately, data are thus far lacking about the
precision of ICG elimination tests in situations with limited
residual hepatic functional reserves.5,7 We sought to test the
accuracy of ICG-PDR measurements by pulse spectropho-
tometry in a situation without hepatic perfusion and/or
excretion and thus tested the hypothesis that ICG-PDR is
zero or close to zero in patients during the anhepatic phase
of orthotopic liver transplantation (OLT).
Materials and Methods
A total of 24 consecutive patients who underwent OLT
between March 2005 and April 2007 in our institution were
included in the current study after giving informed consent
(institutional approval: 1.05.01.30.-17).
During the anhepatic phase of OLT, noninvasive
measurement of ICG-PDR was performed in all patients.
We rapidly injected 25 mg of ICG (Monopeak Indocyanine
Green, SERB SA, Paris) in a constant volume of 10 ml
saline via the jugular catheter. Urine concentrations of ICG
were measured in four patients after ICG injection.
ICG Pulse Spectrophotometry
Pulse-dye densitometry (LiMON, Pulsion Medical Sys-
tems, Munich, Germany) was used for transcutaneous
noninvasive measurement of the blood ICG concentration.
During the first 5–10 min after intravenous injection, ICG
concentrations were monitored at every pulse interval via
pulse spectrophotometry. ICG-PDR as a relative measure
describes fading of the initial ICG concentration (normal-
ized to 100%) and is expressed as percentage change over
time. Because ICG-PDR=100×k=100×ln 2 / t1/2, k (elim-
ination rate constant) and t1/2 (half-life), which have been
Table 1 The Demographic Data of all Patients
N Diagnosis Age (years) Gender BMI (kg/m2)
1 CHC 64 F 25.8
2 CHC/HCC 49 M 28.0
3 CHC 47 M 27.0
4 CHC/ETC 39 F 25.1
5 CHB/HCC 48 M 27.9
6 NASH 53 M 46.0
7 CHC/HCC 66 M 20.8
8 CHC/CHB 50 F 29.3
9 IP 40 F 20.9
10 CHC 62 M 29.4
11 PBC 63 F 22.1
12 CC 56 F 24.0
13 ETC 55 M 24.1
14 MCLC 62 F 25.5
15 CHC 57 M 34.8
16 ETC 53 F 24.7
17 IP 57 F 25.0
18 CHB/HCC 49 F 30.4
19 CHC/HCC 68 M 27.0
20 PBC 59 F 19.0
21 AIH 69 F 22.0
22 UC 61 M 24.0
23 CHB 41 M 28.0
24 NASH 59 F 29.0
Mediana – 56 (49–62) – 26.4 (24.7–28.0)
CHC: chronic hepatitis C, CHB: chronic hepatitis B, ETC: ethyltoxic
cirrhosis, PBC: primary biliary cirrhosis, NASH: nonalcoholic steato-
hepatitis cirrhosis, CC: cryptogenic cirrhosis, MCLC: multiple
congenital liver cysts, IP: intoxication with paracetamol, AIH:
autoimmune hepatitis, UC: diagnosis unclear, F: female, M: male,
BMI: body mass index
aMedian is without patients 11 and 15 (the outliers), and 9 and 12
(unstable signal). Values in parentheses are the 95%CI.
Figure 1 The indocyanine green plasma disappearance rate (ICG-
PDR) values during the anhepatic phase of orthotopic liver transplan-
tation in 22 patients are shown. The extent of the box indicates the
25th and 75th percentiles (inner-quartile range). The line inside the
box shows the value of the 50th percentile (median). Capped bars
indicate the last observations that are within the inner fence (25th or
75th, respectively, ±1.5 times the inner-quartile range), and symbols
mark outliers (beyond inner fence).
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used in earlier publications, can easily be derived. Normal
values for ICG blood clearance are considered to be
>18%/min.6
Spectrophotometric Measurement of ICG in Urine
Urine was collected for 115 to 210 min after injection of the
dye. Samples were afterwards centrifuged. The ICG
concentration in the supernatant was read against the blank
at 800 nm on a Perkin Elmer Lambda 15 (Waltham, MA,
USA) photometer.
Renal ICG-PDR (ICG-PDRr) was calculated from the
absolute ICG amount in urine (u) collected over a time
period (t) after the injection of a dose (d) according to the
equation:
ICGPDRr ¼ 100 1 d  uð Þ=dð Þ1=t 
Statistical Analysis
Data are presented as the median with the 95%CI in
parentheses. Values beyond the inner fence (25th or 75th
Table 2 Results of Spectrophotometry and Possible Influencing Parameters
N ICG PDR
(%/min)
PCSa NEb (μg/h) Blood lossc (ml) FFPd (unit) Albumine (g/l) Δ weightf (kg)
1 2.2 Yes 1,200 1,000 0 26 4.3
2 2.6 No 0 300 0 25 3.8
3 0.2 Yes 1,000 1,000 4 30 0.2
4 2.5 Yes 800 2,000 6 24 0.2
5 0.8 No 400 300 0 25 4.1
6 1.0 No 1,500 2,500 22 24 −1.0
7 0.9 No 0 500 0 43 4.2
8 1.9 Yes 1,200 1,500 2 19 8.0
9 i.s. No 1,000 200 0 n.a. n.a.
10 2.5 Yes 800 1,700 4 18 −0.9
11 5.4 Yes 600 150 0 10 3.7
12 i.s. Yes 400 1,200 3 n.a. n.a.
13 0.8 Yes 240 1,700 0 25 0.5
14 2.9 Yes 140 1,200 0 20 5.6
15 7.8 Yes 80 5,000 9 28 −0.2
16 0.2 Yes 0 2,250 0 25 9.1
17 2.0 No 100 1,300 0 21 0.7
18 2.5 Yes 0 1,000 0 21 0.8
19 1.5 No 600 2,300 0 22 −3.0
20 0.6 Yes 100 800 5 21 n.a.
21 1.0 Yes 200 1,000 0 19 5.6
22 1.7 Yes 360 500 8 27 0.7
23 1.6 Yes 50 PE 2,300 5 24 3.1
24 0.7 Yes 180 3,000 5 21 1.1
Mediang 1.55
(0.8–2.2)
n.a. 240
(100–800)
1,250
(1,000–2,000)
0 (0–5) 24 (21–25) 1.1 (0.2–4.2)
Correlation
with ICG-PDR
(R2)h
n.a. p>0.05i 0.003
(p>0.05) j
0.023 (p>0.05) j 0.021 (p>0.05) j 0.112 (p>0.05) j 0.008 (p>0.05) j
ICG-PDR: indocyanine green plasma disappearance rate, i.s.: instable signal, PCS: portacaval shunt, NE: norepinephrine, PE: phenylephrine,
FFP: fresh frozen plasma, n.a.: not available
a Application of PCS during anhepatic phase.
b Application of NE dose during anhepatic phase.
c Blood loss from the beginning of the operation until the anhepatic phase.
d Administered units of FFP from the beginning of the operation until the anhepatic phase.
e Albumin (serum) on third postoperative day.
fΔ weight = difference of body weight before and 3 days after the operation.
gMedian is without patients 11 and 15 (the outliers), and 9 and 12 (unstable signal). Values in parentheses are the 95%CI.
h Coefficient of determination.
iWilcoxon rank-sum test.
j t-test.
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percentiles, respectively, ±1.5 times the inner-quartile
range) were defined as outliers. Normality of data was
proved with the Kolmogorov–Smirnov and D’Agostino
Kurtosis tests. Descriptive statistics, group comparisons
(Wilcoxon rank-sum test), and linear regressions were made
using statistical software (NCSS 2004, Kaysville, Utah,
USA). To test the linear regression, the coefficient of
determination (R2=square of the correlation coefficient)
was determined and its significance tested with a t-test.
Results
The indications for OLT and the demographic data of all 24
patients are shown in Table 1. Two patients had to be
excluded from further analysis because of an unstable
percutaneous ICG signal.
After exclusion of two outliers as shown in Fig. 1 (ICG-
PDR=5.4%/min and 7.8%/min), the median ICG-PDR was
1.55%/min (95%CI=0.8–2.2).
We performed univariate linear regression analysis with
the following independent variables: norepinephrine during
the anhepatic phase of OLT, blood loss, units of fresh
frozen plasma given until the anhepatic phase, serum
albumin on the third postoperative day, body weight before
and 3 days after the operation, the time course of liquid
balance (not depicted), and the tidal volume during the
anhepatic phase (not depicted). As Table 2 shows, we
identified no correlation of any of these variables with ICG-
PDR (%/min); all coefficient of determination (R2) values
were close to zero and p>0.05. Furthermore, we found no
difference in ICG-PDR between the groups with or without
application of a temporary portacaval shunt (p>0.05).
The renal ICG-PDRr was found to be minute in
comparison to the ICG-PDR values derived from the pulse
spectrometer (Fig. 2, Table 3).
Discussion
Using a commercially available bedside monitor system,
we unexpectedly found that ICG-PDR values showed
considerable variability and differed from zero in the
anhepatic phase of OLT in 22 patients. Of all the examined
clinical cofactors, we found no correlation with ICG-PDR.
Because neither blood loss nor administration of fresh
frozen plasma before the anhepatic phase seemed to
influence ICG-PDR, dilution during the measurement as a
consequence of volume challenge after hemorrhage does
not explain the ICG-PDR values different from zero.
Alterations of the otherwise high protein binding of ICG
as a consequence of volume or fresh frozen plasma
administration are thus also very unlikely as an explanation
for our findings.23
In addition, the tidal volume and therefore hypocapnia or
hypercapnia do not affect ICG elimination by mechanisms
other than changes in hepatic flow and hepatic function, as
has already been established in an animal model.24
Catecholamines and a temporary portacaval shunt seem to
influence ICG-PDR only via changes in hepatic perfu-
sion.25,26 The extremely low amounts of ICG found in urine
in our experiments also exclude renal excretion as a reason
for the observed plasma disappearance of ICG. Technical
failure because of detecting probe malpositioning and
patient movement are excludable because the pulse spec-
trophotometer system used in this study does not allow
measurements with weak or inconsistent signals. Sponta-
neous decay of ICG is also a rather implausible explanation
Figure 2 Histogram of ICG-PDR values with density trace (black
line) and dot plot along the horizontal axis (raw data).
Table 3 ICG Measurement in Urine in Four Patients
ICG-PDRa
(%/min)
Timeb (min) ICG in urinec (mg) ICG-PDRr
d
(%/min)
1 115 0.050 0.0017
1.7 120 0.011 0.0004
1.6 120 0.003 0.0001
0.7 210 0.047 0.0009
a ICG-PDR was measured by pulse spectrophotometry (LiMON).
b Urine was collected during roughly (time) 2 h after ICG injection.
c The total amount of ICG in urine was determined by photo-
spectrometry.
d Based on this amount of ICG, the renal ICG-PDRr was then
calculated according to the equation described in the “Materials and
Methods” section and was found to be minute in comparison to the
ICG-PDR values computed by LiMON.
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for the disappearance of ICG because it remains stable for
at least 4 h.27
However, our results are consistent with the findings
of Stehr et al.23 who described in a hyperdynamic porcine
endotoxemia model an ICG-PDR increase although hepatic
function assessed by measurement of biliary ICG excretion
clearly decreased. Diffusion of the free or even the
albumin-bound fraction of ICG to the interstitial space
through an endothelial leak in the context of a perioper-
ative systemic inflammatory response syndrome may
explain the overestimation of ICG-PDR.28 Furthermore,
as reported by other authors, considerable temporary
redistribution of ICG in animal models into extrahepatic–
extravascular tissue may also assume importance in this
context.29,30 To explain the outcome in this study,
therefore, we postulated a capillary leak with extravasation
of protein-bound ICG into the interstitial space.31,32 Thus,
we examined the correlation of ICG-PDR to (1) sequential
postoperative serum albumin values, (2) differences in
body weight before and after OLT, and (3) the post-OLT
course of liquid balances. Neither albumin nor the clinical
parameters correlated statistically with the ICG-PDR
values. However, the difficulty of quantitatively assessing
the capillary leak is well recognized.33
According to our findings, the precision of the correla-
tion of ICG-PDR and functional hepatic reserve must be
questioned. Our results are even more remarkable because
hepatic perfusion was eliminated as a parameter influencing
PDR. Overestimation of residual liver function may occur
in situations with a possible capillary leak (e.g., sepsis,
anaphylaxis, or perioperative systemic inflammatory re-
sponse syndrome). Because misinterpretation of hepatic
function is a crucial issue, especially in the small-for-size
liver remnant scenarios with marginal residual hepatic
reserves, a possible inaccuracy of up to 1.55%/min on
average has to be taken into account if ICG pulse
spectrophotometry is used to determine functional hepatic
reserve. It is important to recognize that this value
corresponds to 31% of an ICG-PDR of 5.0%/min, which
is considered the crucial cutoff point for a favorable
outcome after major liver resection.19
Conclusion
During the anhepatic phase of OLT, ICG-PDR values were
unexpectedly found to be considerably different from zero.
Apart from hepatic perfusion and functional hepatic
reserve, other factors seem to influence real-time ICG-
PDR determined by pulse spectrophotometry. These cofac-
tors increase in importance with low ICG-PDR values and
must be taken into account when determining the functional
hepatic reserve in liver insufficiency or when assessing the
minimally required hepatic mass during extended liver
resection.
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